Skip to main content

Cogent Biosciences, Inc.

corporate_fare Company Profile

Cogent Biosciences, Inc.

COGT·NASDAQ·Life Sciences·CIK 0001622229

Cogent Biosciences, Inc. is a clinical-stage biotechnology company that develops precision therapies for genetically defined diseases. The company's most advanced program is bezuclastinib (also known as CGT9486), a highly selective tyrosine kinase inhibitor. Bezuclastinib is designed to inhibit the KIT D816V mutation and other mutations in KIT exon 17. The KIT D816V mutation drives Systemic Mastocytosis ("SM"), a rare disease, and exon 17 mutations are found in patients with advanced gastrointestinal stromal tumors ("GIST"). Cogent Biosciences is developing bezuclastinib to treat patients with Non-Advanced Systemic Mastocytosis ("NonAdvSM"), Advanced Systemic Mastocytosis ("AdvSM"), and GIST. In 2025, the company reported positive top-line results from registrational trials for these indications. Cogent Biosciences plans to launch bezuclastinib commercially in the United States in the second half of 2026, subject to regulatory approval. The company also has an ongoing Phase 1 study for its internally developed FGFR2/3 inhibitor and has started a Phase 1 study for its CNS-penetrant, selective mutant ErbB2 inhibitor. Additionally, the Cogent Research Team is developing a portfolio of novel targeted therapies for mutations in PI3Kα, KRAS, and JAK2.

Cogent Biosciences, Inc. (NASDAQ:COGT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for COGT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for COGT spans 10-Q, 8-K, DEF 14A, 144.

Recent high-impact activity:

  • Cogent 10-Q: Q3 Loss Widens to $111.4M; $791.1M Cash Funds Operations Into Late 2028
  • Cogent Q3 Loss Widens to $111M as Three FDA Decisions Loom
  • FDA Accepts Cogent's Bezuclastinib NDA for Advanced Systemic Mastocytosis, Sets June 2027 Decision Date
  • Cogent Biosciences Q2 loss widens to $96.4M; cash runway extends into 2028 ahead of key FDA decisions
  • Cogent Biosciences Q2 2026: $96.4M Net Loss, $865.9M Pro Forma Cash, and PDUFA Dates Set for Bezuclastinib

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$328.94M
Diluted EPS
-$2.16
Op. Cash Flow
-$264.44M
Free Cash Flow
-$266M
Operating Income
-$333.36M
Cash & Equivalents
$312.01M
Total Debt
$222.9M
Debt / Equity
0.35×
Shares Outstanding
160.98M sh
Source: 10-K · filed 2026-02-17 · accession 0001193125-26-053334

Short Interest & Short Volume

8.68 days to cover

FINRA reported short interest of 17,416,118 shares in COGT as of the October 30, 2026 settlement, a 11.4% decrease from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 22.2% of COGT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,416,118 shares as of October 30, 2026
Change vs prior period▼ 11.4%
Days to cover8.68 at avg daily volume of 2,005,883
Daily short volume (FINRA facilities)22.2% of 965,549 shares on November 20, 2026
5-day average short volume34.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for COGT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.

1 recent capital raise

$400M ATM Prospectus Supplement Filed · Potential Dilution of ~5.6%

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$27.2 +1.82% today
52-week range · as of 2026-11-05 $13.78 – $43.73
Market cap
$4.65B
Volume
2.1M (1.0× avg)
3-mo avg 2.2M
Live data · 2026-11-22 11:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COGT - Latest Insights

COGT
Nov 05, 2026, 4:28 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $27.20 info
Change: -$2.01 (-7%) info
Market Cap: $4.648B info
COGT
Nov 05, 2026, 4:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $27.20 info
Change: -$2.01 (-7%) info
Market Cap: $4.648B info
COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $27.20 info
Change: -$6.30 (-19%) info
Market Cap: $4.648B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $27.20 info
Change: -$14.33 (-35%) info
Market Cap: $4.648B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $27.20 info
Change: -$13.35 (-33%) info
Market Cap: $4.648B info
COGT
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $38.60
Real-time Price: $27.20 info
Change: -$11.40 (-30%) info
Market Cap: $4.648B info
COGT
May 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $34.91
Real-time Price: $27.20 info
Change: -$7.71 (-22%) info
Market Cap: $4.648B info
COGT
May 05, 2026, 8:21 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.86
Real-time Price: $27.20 info
Change: -$9.66 (-26%) info
Market Cap: $4.648B info
COGT
May 05, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $36.57
Real-time Price: $27.20 info
Change: -$9.37 (-26%) info
Market Cap: $4.648B info
COGT
Apr 23, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $35.24
Real-time Price: $27.20 info
Change: -$8.04 (-23%) info
Market Cap: $4.648B info
COGT
Apr 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $38.49
Real-time Price: $27.20 info
Change: -$11.29 (-29%) info
Market Cap: $4.648B info
COGT
Mar 31, 2026, 9:30 PM EDT
Filing Type: 144
Importance Score:
9
Price at Filing: $38.50
Real-time Price: $27.20 info
Change: -$11.30 (-29%) info
Market Cap: $4.648B info
COGT
Mar 31, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $38.50
Real-time Price: $27.20 info
Change: -$11.30 (-29%) info
Market Cap: $4.648B info
COGT
Mar 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $34.60
Real-time Price: $27.20 info
Change: -$7.40 (-21%) info
Market Cap: $4.648B info
COGT
Feb 17, 2026, 9:24 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $36.49
Real-time Price: $27.20 info
Change: -$9.29 (-25%) info
Market Cap: $4.648B info
COGT
Feb 17, 2026, 8:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.49
Real-time Price: $27.20 info
Change: -$9.29 (-25%) info
Market Cap: $4.648B info
COGT
Jan 22, 2026, 8:09 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $39.53
Real-time Price: $27.20 info
Change: -$12.33 (-31%) info
Market Cap: $4.648B info
COGT
Jan 22, 2026, 8:05 PM EST
Filing Type: 144
Importance Score:
8
Price at Filing: $39.53
Real-time Price: $27.20 info
Change: -$12.33 (-31%) info
Market Cap: $4.648B info
COGT
Jan 22, 2026, 8:02 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $39.53
Real-time Price: $27.20 info
Change: -$12.33 (-31%) info
Market Cap: $4.648B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets